Department of Community Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Golgasht Ave., Tabriz, Iran.
Arch Virol. 2010 Mar;155(3):329-34. doi: 10.1007/s00705-009-0583-6. Epub 2010 Jan 6.
We performed a pilot surveillance study on transmitted HIV drug resistance (TDR) in Iran, with specimens collected and stored as dried blood spots (DBS). The protease region and relevant positions in the reverse transcriptase region of the pol gene were sequenced to detect mutations known to be associated with resistance to drugs in standard first-line regimens. Seventy-three specimens were collected, with 39 (53%) specimens yielding sequence from both protease and at least part of RT. Specimens were almost exclusively HIV-1 subtype CRF 35_A1D based on pol sequencing. Mutations were restricted to RT, with D67DG and V75AV each seen in a single specimen. An atypical protease inhibitor mutation, I47M, appeared at a resistance-associated position in protease from a single specimen. These preliminary data showed that the rate of transmitted drug resistance in Iran, within the areas sampled, was 5.1% (2/39). However, the small sample size makes this figure only an approximation. Due to the sampling strategy and resulting small sample size, we were unable to accurately calculate TDR rates for individual areas using the WHO HIV drug resistance threshold survey method. Increasing the sample size and improving the yield from DBS would improve the accuracy of drug resistance surveillance and facilitate wider application of this methodology in Iran.
我们在伊朗进行了一项关于传播的 HIV 耐药性(TDR)的试点监测研究,采集并储存了干燥血斑(DBS)标本。对 pol 基因的蛋白酶区域和逆转录酶区域的相关位置进行了测序,以检测与标准一线治疗方案中耐药性相关的已知突变。共采集了 73 份标本,其中 39 份(53%)标本同时从蛋白酶和至少部分 RT 区域获得了序列。基于 pol 测序,标本几乎完全是 HIV-1 亚型 CRF 35_A1D。突变仅限于 RT,D67DG 和 V75AV 各在一个标本中出现。在单个标本的蛋白酶中,出现了一个不典型的蛋白酶抑制剂突变 I47M,该突变出现在与耐药性相关的位置。这些初步数据显示,在所采样的伊朗地区,传播的耐药率为 5.1%(2/39)。然而,由于样本量小,这个数字只是一个近似值。由于采样策略和由此产生的小样本量,我们无法使用世卫组织 HIV 耐药性阈值调查方法准确计算各个地区的 TDR 率。增加样本量并提高 DBS 的产量将提高耐药性监测的准确性,并促进该方法在伊朗的更广泛应用。